非酒精性脂肪性肝病中的奥贝胆酸和白藜芦醇：闪光的不一定都是金子，徘徊的人不一定都迷失。 - Suppr | 超能文献

Obeticholic acid and resveratrol in nonalcoholic fatty liver disease: all that is gold does not glitter, not all those who wander are lost.

作者信息

Musso Giovanni

机构信息

Gradenigo Hospital, Torino, Italy.

出版信息

Hepatology. 2015 Jun;61(6):2104-6. doi: 10.1002/hep.27772. Epub 2015 Apr 8.

DOI:10.1002/hep.27772

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

Obeticholic acid and resveratrol in nonalcoholic fatty liver disease: all that is gold does not glitter, not all those who wander are lost.非酒精性脂肪性肝病中的奥贝胆酸和白藜芦醇：闪光的不一定都是金子，徘徊的人不一定都迷失。

Hepatology. 2015 Jun;61(6):2104-6. doi: 10.1002/hep.27772. Epub 2015 Apr 8.

2

NAFLD: obeticholic acid for the treatment of fatty liver disease--NASH no more?非酒精性脂肪性肝病：奥贝胆酸用于治疗脂肪性肝病——非酒精性脂肪性肝炎不再适用了吗？

Nat Rev Gastroenterol Hepatol. 2015 Jan;12(1):1. doi: 10.1038/nrgastro.2014.203. Epub 2014 Nov 25.

3

Obeticholic acid for the treatment of nonalcoholic steatohepatitis.奥贝胆酸用于治疗非酒精性脂肪性肝炎。

Expert Rev Gastroenterol Hepatol. 2020 May;14(5):311-321. doi: 10.1080/17474124.2020.1748498. Epub 2020 May 12.

4

Emerging role of obeticholic acid in the management of nonalcoholic fatty liver disease.奥贝胆酸在非酒精性脂肪性肝病管理中的新作用。

World J Gastroenterol. 2016 Nov 7;22(41):9039-9043. doi: 10.3748/wjg.v22.i41.9039.

5

Farnesoid X receptor targeting to treat nonalcoholic steatohepatitis.法尼醇 X 受体靶向治疗非酒精性脂肪性肝炎。

Drug Discov Today. 2012 Sep;17(17-18):988-97. doi: 10.1016/j.drudis.2012.05.012. Epub 2012 May 29.

6

Use of farnesoid X receptor agonists to treat nonalcoholic fatty liver disease.使用法尼醇X受体激动剂治疗非酒精性脂肪性肝病。

Dig Dis. 2015;33(3):426-32. doi: 10.1159/000371698. Epub 2015 May 27.

7

Obeticholic acid for the treatment of nonalcoholic steatohepatitis: Expectations and concerns.用于治疗非酒精性脂肪性肝炎的奥贝胆酸：期望与担忧。

Metabolism. 2020 Mar;104:154144. doi: 10.1016/j.metabol.2020.154144. Epub 2020 Jan 11.

8

Farnesoid X nuclear receptor agonists for the treatment of nonalcoholic steatohepatitis.法尼醇 X 核受体激动剂治疗非酒精性脂肪性肝炎。

Eur J Pharmacol. 2019 Nov 15;863:172661. doi: 10.1016/j.ejphar.2019.172661. Epub 2019 Sep 16.

9

The use of obeticholic acid for the management of non-viral liver disease: current clinical practice and future perspectives.奥贝胆酸用于非病毒性肝病的治疗：当前的临床实践和未来展望。

Expert Rev Gastroenterol Hepatol. 2018 Feb;12(2):165-171. doi: 10.1080/17474124.2018.1399060. Epub 2017 Nov 3.

10

Nuclear receptors: how do they position in non-alcoholic fatty liver disease treatment?核受体：它们在非酒精性脂肪性肝病治疗中处于何种地位？

Liver Int. 2014 Oct;34(9):1291-4. doi: 10.1111/liv.12578.

引用本文的文献

1

Resveratrol Ameliorates Experimental Alcoholic Liver Disease by Modulating Oxidative Stress.白藜芦醇通过调节氧化应激改善实验性酒精性肝病。

Evid Based Complement Alternat Med. 2017;2017:4287890. doi: 10.1155/2017/4287890. Epub 2017 Dec 31.

2

Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies.非酒精性脂肪性肝炎：新兴的分子靶点和治疗策略。

Nat Rev Drug Discov. 2016 Apr;15(4):249-74. doi: 10.1038/nrd.2015.3. Epub 2016 Jan 22.